Assessing IT-business alignment in service-oriented Enterprises

Nowadays, more and more businesses transform into service-oriented enterprises in order to sustain their competitive advantage. To ensure that the underlying information technology (IT) can best support the transformation, we aim to develop an IT-business alignment framework to assess the quality of alignment in the context of service-oriented enterprises. Based upon the existing literature, we propose three components of IT-business alignment: strategic alignment, operational alignment, and social alignment. We study their various contributions to the performance of service-oriented IT projects, together with the interactions with service integration level.Our data were collected from Web questionnaires. The total dataset is derived from 300 selected companies in an on-line technology management forum. Among the returned questionnaires, 104 were found to be complete and usable; this represented a response rate of 34 percent.A Partial Least Squares (PLS) analysis is conducted and derives the following three research findings: (1) IT-business alignment plays a significant role in improving the performance of service-oriented IT; (2) the service integration level is an important performance moderator for strategic and operational alignment; (3) the service integration level is an important contributor to social alignment. Available at: https://aisel.aisnet.org/pajais/vol3/iss1/3

Exploring risk factors in implementing service-oriented IT projects

For IT project managers, how to implement IT projects successfully is always an important issue due to high failure rate of traditional IT project implementation. When more and more enterprises start to develop systems under the new IT methodology in service oriented IT projects, it is essential to access risks coming with this new IT concept. In this research we aim to identify risk factors related to service oriented IT projects and then analyze the impact and rank of these risk factors. Adapted from the general IT project risk category proposed by Ewusi (1994), we propose 6 risk factors of service-oriented IT projects. The risk framework highlights the properties of business strategy, business Process, and workforce under on-demand business architecture. We use a customer service system to justify our research framework, applying the IBM’s concept of SIMM (service integrated maturity model). A pretest is first conducted with several IT experts who has implemented service oriented IT project experience, followed by a general survey. A binary logistic regression is used to testify the hypotheses. The result shows that essential risk factors that influence the adoption of service oriented system, from the highest to lowest, are insufficient technology planning, lack of expertise, ineffective project governance, and organizational misalignment. The findings help CIOs and project managers realize of the risks and the priority of these risks that have to be noticed and controlled when making decisions on service oriented systems adoption

Association of a Lymphotoxin-α Gene Polymorphism and Atopic Asthma in Taiwanese Children

The lymphotoxin-α (LT-α) gene is located on chromosome 6 (6p21.1–6p21.3) and it may regulate tumor necrosis factor (TNF) production. TNF is a potent cytokine in the airway inflammatory response. Polymorphisms of TNF-associated genes have been related to asthma. This study investigated an LT-α-NcoI polymorphism in the first intron of the LT-α gene (LT-α-NcoI*1 allele, as a variant type; and LT-α-NcoI*2 allele), which may predispose individuals to asthma and atopy. Methods: Polymerase chain reaction-based assays were performed to determine LT-α-NcoI genotypes among our subjects. A genetic case control analysis was then performed on 114 atopic asthmatic and 155 non-asthmatic unrelated children. Results: There was a statistically higher frequency of LT-α-NcoI*1 allele carriers (1/1 + 1/2) in the subjects with atopic asthma than in controls (OR = 1.923; 95% CI = 1.061–3.484; p = 0.031). Conclusion: The results indicate that LT-α-NcoI*1 may be a risk factor for atopic asthma in Taiwanese children

Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4–48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study

Objective: The main objective of this study was to evaluate the efficacy and safety of Lactobacillus rhamnosus in children aged 4–48 months with atopic dermatitis. Methods: The design of this study was a two-center, double-blind, randomized, and placebo-controlled study with two parallel groups to evaluate the efficacy and safety profile of L. rhamnosus in children aged 4–48 months with atopic dermatitis diagnosed using Hanifin and Rajka criteria and with a Scoring of Atopic Dermatitis (SCORAD) ≥ 15 at enrollment. The duration of this study was 8 weeks with a total of five visits. The enrolled patients were allocated into either a treatment group (one ComProbi capsule containing L. rhamnosus a day) or a control group (one capsule of placebo a day) at a ratio of 1:1. The primary endpoint was to compare the mean change from baseline in SCORAD after 8 weeks of treatment. The other secondary end points were to compare the following: the mean changes from baseline in SCORAD at postbaseline visits, the frequency and total amount of the use of corticosteroids during the 8-week treatment, the frequency of atopic dermatitis and the symptom-free duration, the mean changes from baseline in Infant Dermatitis Quality of Life Questionnaire at Week 4 and Week 8, and the mean changes from baseline in the Dermatitis Family Impact Questionnaire at Week 4 and Week 8. Results: The mean changes in SCORAD from baseline at Week 8 was −21.69 ± 16.56 in the L. rhamnosus group and −12.35 ± 12.82 in the placebo group for the intent-to-treat population (p = 0.014). For the per-protocol population, the mean change of SCORAD from baseline was −23.20 ± 15.24 in the L. rhamnosus group and −12.35 ± 12.82 in the placebo group (p = 0.003). Significant differences were demonstrated between groups at Week 8 in intensity in the intent-to-treat population and per-protocol population. Throughout the period, the amount of topical corticosteroids used showed no difference between groups. No significant difference was noted in the overall symptom-free durations compared with the placebo group. Infant Dermatitis Quality of Life Questionnaires and Dermatitis Family Impact Questionnaires scores improved significantly at Week 4 and Week 8 but did not reach statistical significance. Adverse events were documented in 14/33 patients in the L. rhamnosus group (42.42%, 35 events) and in 15/33 placebo patients (45.45%, 37 events). Conclusions: The results of this study indicated that L. rhamnosus was effective in decreasing symptoms of atopic dermatitis after an 8-week treatment by comparing the mean change of SCORAD from baseline with a placebo (p < 0.05). The reduction in SCORAD resulted from a consistent decrease in all components of SCORAD. Patients who took L. rhamnosus for 8 weeks expressed less SCORAD in the three components: area of affected skin, intensity of atopic dermatitis, and patient symptoms, with a significant decrease in the mean change of intensity from baseline compared with placebo